JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma

Neuro-Oncology

Volumn 16, Issue 9, 2014, Pages 1229-1243

  Zheng, Qifan ^a,b   Han, Lei ^d,e,f,g   Dong, Yucui ^a,b   Tian, Jing ^a,b   Huang, Wei ^a,b   Liu, Zhaoyu ^a,b   Jia, Xiuzhi ^a,b   Jiang, Tao ^c,g   Zhang, Jianning ^d,e,f   Li, Xia ^a   Kang, Chunsheng ^d,e,f,g   Ren, Huan ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Heilongjiang Provincial Key Laboratory for Infection and Immunity   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

^e Tianjin Neurological Institute   (China)

^f BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^g Chinese Glioma Cooperative Group (CGCG)   (China)

Author keywords

EGFRvIII; Focal adhesion; Glioblastoma; Invasion; JAK2 STAT3

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GELATINASE A; GELATINASE B; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; MESSENGER RNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PYRROLIDINE DITHIOCARBAMATE; RAPAMYCIN; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG; WP 1066; ALPHA-CYANO-(3,4-DIHYDROXY)-N-BENZYLCINNAMIDE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; STAT3 PROTEIN, HUMAN; TYRPHOSTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SHAPE; CELL STRUCTURE; CONTROLLED STUDY; FEMALE; FOCAL ADHESION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; GLIOBLASTOMA; IN VITRO STUDY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR INVASION; WESTERN BLOTTING; ANIMAL; BRAIN NEOPLASMS; DRUG EFFECTS; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; ENZYME INHIBITORS; FOCAL ADHESIONS; GLIOBLASTOMA; HUMANS; JANUS KINASE 2; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TYRPHOSTINS;

EID: 84907003914     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou046     Document Type: Article

References (47)

1. Chow LM, Endersby R, Zhu X, et al. Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell. 2011;19(3):305-316.
2. Huang PH, Xu AM, White FM. Oncogenic EGFR signaling networks in glioma. Sci Signal. 2009;2(87):re6.
3. Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 2009;16(6):748-754.
4. Van Meter TE, Broaddus WC, Rooprai HK, et al. Induction of membrane-type-1 matrix metalloproteinase by epidermal growth factor-mediated signaling in gliomas. Neuro Oncol. 2004;6(3):188-199. (Pubitemid 39136502)
5. Lal A, Glazer CA, Martinson HM, et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 2002;62(12):3335-3339. (Pubitemid 34651373)
6. Wheeler SE, Morariu EM, Bednash JS, et al. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer. Clin Cancer Res. 2012;18(10):2850-2860.
7. Ning Y, Zeineldin R, Liu Y, et al. Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. Cancer Res. 2005;65(20):9280-9286. (Pubitemid 41507994)
8. Zagzag D, Friedlander DR, Margolis B, et al. Molecular events implicated in brain tumor angiogenesis and invasion. Pediatr Neurosurg. 2000;33(1):49-55.
9. Liu M, Yang Y, Wang C, et al. The effect of epidermal growth factor receptor variant III on glioma cell migration by stimulating ERK phosphorylation through the focal adhesion kinase signaling pathway. Arch Biochem Biophys. 2010;502(2):89-95.
10. Lu KV, Zhu S, Cvrljevic A, et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res. 2009;69(17):6889-6898.
11. Kwiatkowska A, Symons M. Signaling determinants of glioma cell invasion. Adv Exp Med Biol. 2013;986:121-141.
12. Cai XM, Tao BB, Wang LY, et al. Protein phosphatase activity of PTEN inhibited the invasion of glioma cells with epidermal growth factor receptor mutation type III expression. Int J Cancer. 2005;117(6):905-912.
13. Chung BM, Dimri M, George M, et al. The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants. Oncogene. 2009;28(16):1821-1832.
14. Groner B, Lucks P, Borghouts C. The function of Stat3 in tumor cells and their microenvironment. Semin Cell Dev Biol. 2008;19(4):341-350.
15. Swiatek-Machado K, Kaminska B. STAT signaling in glioma cells. Adv Exp Med Biol. 2013;986:189-208.
16. Lo HW, Cao X, Zhu H, et al. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res. 2008;14(19):6042-6054.
17. de la Iglesia N, Konopka G, Puram SV, et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev. 2008;22(4):449-462. (Pubitemid 351272753)
18. Fan QW, Cheng CK, Gustafson WC, et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell. 2013;24(4):438-449.
19. Moghal N, Sternberg PW. Multiple positive and negative regulators of signaling by the EGF-receptor. Curr Opin Cell Biol. 1999;11(2):190-196. (Pubitemid 29164033)
20. Vignais ML, Sadowski HB, Watling D, et al. Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol Cell Biol. 1996;16(4):1759-1769. (Pubitemid 26095648)
21. Yamauchi T, Ueki K, Tobe K, et al. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. Nature. 1997;390(6655):91-96. (Pubitemid 27494763)
22. Heimberger AB, Priebe W. Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers. Recent Pat CNS Drug Discov. 2008;3(3):179-188.
23. Xing WJ, Zou Y, Han QL, et al. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors. Clin Exp Pharmacol Physiol. 2013;40(1):13-21.
24. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
25. Xiong H, Zhang ZG, Tian XQ, et al. Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia. 2008;10(3):287-297. (Pubitemid 351328587)
26. Jia X, Hu M,Wang C, et al. Coordinated gene expression of Th17- and Treg-associated molecules correlated with resolution of the monophasic experimental autoimmune uveitis. Mol Vis. 2011;17:1493-1507.
27. Chen L, Han L, Zhang K, et al. VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1alpha/VEGF and beta-catenin/Tcf-4 signaling. Neuro Oncol. 2012;14(8):1026-1036.
28. Ding X, He Z, Zhou K, et al. Essential role of TRPC6 channels in G2/M phase transition and development of human glioma. J Natl Cancer Inst. 2010;102(14):1052-1068.
29. Levicar N, Nuttall RK, Lah TT. Proteases in brain tumour progression. Acta Neurochir (Wien). 2003;145(9):825-838. (Pubitemid 37204559)
30. Park MJ, Kim MS, Park IC, et al. PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation. Cancer Res. 2002;62(21):6318-6322.
31. Iwamaru A, Szymanski S, Iwado E, et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene. 2007;26(17):2435-2444. (Pubitemid 46597261)
32. Wozniak MA, Modzelewska K, Kwong L, et al. Focal adhesion regulation of cell behavior. Biochim Biophys Acta. 2004;1692(2-3):103-119. (Pubitemid 38891769)
33. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006;18(5):516-523. (Pubitemid 44332916)
34. Badgwell DB, Lu Z, Le K, et al. The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene. 2012;31(1):68-79.
35. Weller M, Stupp R, Hegi M, et al. Individualized targeted therapy for glioblastoma: fact or fiction?. Cancer J. 2012;18(1):40-44.
36. Mukherjee B, McEllin B, Camacho CV, et al. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res. 2009;69(10):4252-4259.
37. Del Vecchio CA, Giacomini CP, Vogel H, et al. EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. Oncogene. 2013;32(21):2670-2681.
38. Kim SH, Turnbull J, Guimond S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol. 2011;209(2):139-151.
39. Sieg DJ, Hauck CR, Ilic D, et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol. 2000;2(5):249-256.
40. Silver DL, Naora H, Liu J, et al. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res. 2004;64(10):3550-3558. (Pubitemid 38657931)
41. Stechishin OD, Luchman HA, Ruan Y, et al. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells. Neuro Oncol. 2013;15(2):198-207.
42. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011;147(5):992-1009.
43. Doucette TA, Kong LY, Yang Y, et al. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol. 2012;14(9):1136-1145.
44. Colomiere M,Ward AC, Riley C, et al. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer. 2009;100(1):134-144.
45. Lindemann C, Hackmann O, Delic S, et al. SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation. Acta Neuropathol. 2011;122(2):241-251.
46. Harada D, Takigawa N, Ochi N, et al. JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation. Cancer Sci. 2012;103(10):1795-1802.
47. Alvarez JV, Greulich H, Sellers WR, et al. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res. 2006;66(6):3162-3168.